In this study, the high-risk group showed a stronger immune response to HLA, para-inflammation, Type I Interferon (IFN), and Type II IFN; in other words, the decline in anti-tumor immune function may lead to a poor prognosis. This evidence concerns the gene IFNA1 and neoplasm.